

(12) United States Patent

Verdonck et al.

US 9.636.341 B2 (10) Patent No.:

(45) Date of Patent: *May 2, 2017

(54) SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE

(71) Applicant: Janssen Pharmaceutica NV, Beerse (BE)

(72) Inventors: Marc Gustaaf Celine Verdonck, Gierle (BE); Patrick Rene Angibaud, Fontaine-Bellenger (FR): Bruno Roux. Saint Leger du Bourg-Denis (FR); Isabelle Noelle Constance Pilatte, Louviers (FR); Peter Ten Holte, Beerse (BE); Janine Arts, Breda (NL); Kristof

Van Emelen, Sint-Niklaas (BE)

(73) Assignee: Janssen Pharmaceutica N.V., Beerse

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

> This patent is subject to a terminal disclaimer.

(21) Appl. No.: 14/831,455

(22)Filed: Aug. 20, 2015

(65)**Prior Publication Data**

US 2015/0342950 A1 Dec. 3, 2015

Related U.S. Application Data

- (60) Division of application No. 14/244,046, filed on Apr. 3, 2014, now Pat. No. 9,150,543, which is a continuation of application No. 13/962,523, filed on Aug. 8, 2013, now abandoned, which is a division of application No. 13/027,793, filed on Feb. 15, 2011, now Pat. No. 8,524,728, which is a continuation of application No. 11/572,563, filed as application No. PCT/EP2005/053612 on Jul. 25, 2005, now Pat. No. 8.193.205.
- Provisional application No. 60/592,182, filed on Jul. 29, 2004.

(30)Foreign Application Priority Data

Jul. 28, 2004 (EP) 04077172

(51) **Int. Cl.** (2006.01)A61K 31/454 C07D 401/14 (2006.01) A61K 31/506 (2006.01)(2006.01)A61K 31/4545 C07D 405/14 (2006.01)C07D 409/14 (2006.01)C07D 491/04 (2006.01)C07D 491/056 (2006.01)

(52) U.S. Cl. CPC A61K 31/506 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 491/04 (2013.01); **C07D** 491/056 (2013.01)

(58) Field of Classification Search

CPC . C07D 401/14; A61K 31/454; A61K 31/4545 USPC 514/275; 544/331 See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

3,331,843 A	7/1967	Tomcufcik et al
3,459,731 A	8/1969	Gramera et al.
3,966,743 A	6/1976	Berger et al.
4,049,811 A	9/1977	Berger et al.
4,348,401 A	9/1982	Friebe et al.
4,455,422 A	6/1984	Banno et al.
5,025,012 A	6/1991	Miura et al.
5,147,876 A	9/1992	Mizuchi et al.
5,338,738 A	8/1994	Matson et al.
5,342,846 A	8/1994	Singh et al.
5,780,454 A	7/1998	Adams et al.
5,789,412 A	8/1998	Halazy et al.
5,952,349 A	9/1999	Asberom et al.
6,066,730 A	5/2000	Adams et al.
6,083,903 A	7/2000	Adams et al.
6,294,538 B1	9/2001	Mylari
6,518,283 B1	2/2003	Langham et al.
	(Continued)	

FOREIGN PATENT DOCUMENTS

2 491 131 CA1/2004 CA 2 518 950 2/2005 (Continued)

OTHER PUBLICATIONS

Pearce et al., Failure modes in anticancer drug discovery and development, Cancer Drug Design and Discovery Edited by Stephen Neidle, Chapter 18, pp. 424-435 (2008).*

(Continued)

Primary Examiner — Deepak Rao

(57)**ABSTRACT**

This invention comprises the novel compounds of formula (I)

wherein R¹, R², R³, X and Y have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

2 Claims, No Drawings